Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

v3.3.1.900
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Operating expenses        
Research and development $ 768,301 $ 667,263 $ 1,813,794 $ 1,217,183
General and administrative 372,342 603,770 1,303,540 1,177,029
Share-based compensation expense (Notes 9(v) and 10) 26,724 13,550 1,695,919 70,679
Depreciation (Note 6) 15,478 11,425 42,892 34,116
Total operating expenses 1,182,845 1,296,008 4,856,145 2,499,007
Other expenses (income)        
Imputed interest expense (Note 7) 0 0 0 30,711
Interest expense 0 0 0 22,269
Other income (5,533) (122,753) (23,156) (624,790)
Change in fair value of warrant derivative liability (Note 11) (3,496,070) 0 1,973,654 0
Total other expenses (income) (3,501,603) (122,753) 1,950,498 (571,810)
Net income (loss) for the period 2,318,758 (1,173,255) (6,806,643) (1,927,197)
Foreign exchange translation adjustment for the period 0 (1,067) 24,799 (4,165)
Net income (loss) and comprehensive income (loss) for the period $ 2,318,758 $ (1,174,322) $ (6,781,844) $ (1,931,362)
Income (loss) per share - basic (Note 2) (in dollars per share) $ 0.03 $ (0.02) $ (0.10) $ (0.04)
Income (loss) per share - diluted (Note 2) (in dollars per share) $ (0.02) $ (0.02) $ (0.10) $ (0.04)
Weighted average number of shares outstanding - basic (Note 2) (in shares) 72,408,313 49,737,096 65,452,924 44,334,936
Weighted average number of shares outstanding - diluted (Note 2) (in shares) 76,270,355 49,737,096 65,452,924 44,334,936